Chris Riley

Chris serves as the Vice President and Group Executive for Danaher’s Genomic Medicines Group, a team comprised of scientific leaders in biological sciences including Aldevron and Integrated DNA Technologies. Our mission is to help our partners accelerate and achieve ground-breaking science in a range of genomics applications including the development and production of novel therapies. Chris joined Danaher in 2007 and is a member of the Danaher Leadership Team. Prior to Genomic Medicines, Chris was responsible for the overall operational results and strategic direction for the Danaher Diagnostics businesses, which includes Beckman Coulter, Cepheid, Leica Biosystems, and Radiometer. Prior to joining Danaher, he worked for The Boston Consulting Group. Chris holds a BS with Honors in Mechanical Engineering from the University of Illinois and has an MBA from Kellogg at Northwestern University.